GlassScriptPhysician profile
Gina Shetty
NPI 1457883860
$9,264.40
in general payments reported to CMS, 2019-2025
18 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $741 · 2023: $1,656 · 2024: $5,326 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,350 · Food and Beverage: $3,896 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,350.00 |
| Food and Beverage | $3,895.84 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $4,683.07 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $757.02 | 2022-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Johnson & Johnson Surgical Vision, INC. | $740.97 | 2021-2025 | Tecnis Iol, Tecnis Iol |
| Alcon Vision LLC | $669.91 | 2021-2025 | Clareon, Tryptyr, Eysuvis |
| Sun Pharmaceutical Industries INC. | $478.39 | 2022-2025 | Cequa |
| Harrow Eye, LLC | $466.00 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $301.00 | 2023-2025 | Envista Mx60 Iol, Vyzulta, Miebo |
| Sight Sciences, INC. | $300.17 | 2022-2023 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $199.81 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $198.55 | 2023 | |
| Oyster Point Pharma, INC. | $168.84 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $109.19 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $58.47 | 2023 | Acuvue |
| Revance Therapeutics, INC. | $33.96 | 2025 | Daxxify |
| Dompe US, INC. | $33.50 | 2024-2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.23 | 2023 | Alphagan P, Vuity, Lumigan |
| Amgen INC. | $25.12 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.